Artiva Biotherapeutics, Inc. ARTV
3.77 USD -0.09 (-2.33%)
Regular-session close
3.77 0.00 0.00%
After hours · Nov 18, 4:01 PM ET
3.75 Day range 3.91
2.96 52-week range 14.53
- YTD
- -12.12%
- 1 year
- -3.08%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Artiva Biotherapeutics, Inc. – ARTV NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Artiva Biotherapeutics, Inc. (“Artiva” or the “Company”) (NASDAQ: ARTV). Such investors are…
businesswire.com ARTV Investors Have Opportunity to Join Artiva Biotherapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ARTV--ARTV Investors Have Opportunity to Join Artiva Biotherapeutics, Inc. Fraud Investigation with SBS Law.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Artiva Biotherapeutics, Inc. ("Artiva" or the "Company") (NASDAQ: ARTV). Such investors are…
benzinga.com Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
benzinga.com Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation Artiva Biotherapeutics ends its AlloNK program after fatal safety events, slashes 94% of its workforce, and weighs strategic liquidation.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Crude Oil Moves Lower; Corning Earnings Top Views U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.benzinga.com Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4 Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…benzinga.com Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation Clinical Development Discontinuation and Patient Follow-UpUpdated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion…
benzinga.com Artiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK Development Strategic Alternatives and Corporate RestructuringArtiva’s Board of Directors is evaluating internal options and potential strategic alternatives intended to maximize stockholder value. Leerink…
benzinga.com Artiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment Pause Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
